Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:06 AM
Ignite Modification Date:
2025-12-25 @ 4:06 AM
NCT ID:
NCT00133302
Eligibility Criteria:
Inclusion Criteria:
* Intermediate- or high-grade non-Hodgkin's lymphoma, excluding cutaneous t-cell lymphoma (CTCL), adult T-cell leukemia-lymphoma (ATL) and T-cell lymphoblastic lymphoma (T-LbL) (Working Formulation)
* Ann Arbor stage: II, III, IV
* No prior chemotherapy or radiotherapy
* Age: 15 to 69
* Performance status (PS): 0, 1, 2
* WBC \>= 3,000 /mm3, ANC \>= 1,200 /mm3, Platelet \>= 75,000 /mm3
* GOT/GPT \<= 5 x Normal Upper Limit, T-Bil \<= 2.0 mg/dL
* Creatinine \<= 2.0 mg/dL
* Normal ECG, Ejection Fraction \>= 50%
* PaO2 \>= 65 mmHg
* Written informed consent
Exclusion Criteria:
* Uncontrollable diabetes mellitus
* Severe complication (infection, heart failure, renal failure, liver failure, etc)
* Anamnesis of heart disease
* Acute or chronic hepatitis, liver cirrhosis and portal hypertension
* Synchronous or metachronous malignancy
* Severe pulmonary dysfunction
* Central nervous system (CNS) invasion
* HIV positive
* Hepatitis B surface antigen (HBs-Ag) positive
* Hepatitis C virus antibody (HCV-Ab) positive
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
15 Years
Maximum Age:
69 Years
Study:
NCT00133302
Study Brief:
Protocol Section:
NCT00133302